Hints and tips:
Related Special Reports
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...Shares in oncology-focused biotech Seagen, which Pfizer has agreed to buy for $43bn, also fell amid fears the agency could target other deals in the sector....
...The official said the companies had capitalised on their market power and deployed the “usual pharma rhetoric . . . Vaccines work so they increased the ‘value’.”...
...“Access to Paxlovid shouldn’t be determined by people’s power or wealth,” said Jin Dongyan, a virologist at the University of Hong Kong....
...There’s much to do before Oklo’s modular nuclear power generation can become reality, as Lex explains. The most imminent is convincing AltC shareholders that they shouldn’t redeem their cash....
...Innovator’s Power Buffer ETFs have largely shielded investors from losses so far....
...But mild over-the-counter remedies have lost their power to make shareholders in Johnson & Johnson feel good....
...“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren said....
...President Joe Biden has invoked the Defense Production Act to ensure that vaccine makers get the drugs and production capacity they need but one industry executive estimated that the use of Korean war-era powers...
...That implies considerable pricing power. Vaccine makers’ ability to pivot quickly could prove a significant advantage, and good news for shareholders....
...Pfizer didn’t fall as much because of its wider array of products....
...The Korean Wave opens September 24, V&A ‘Make, Break, Remix: The Rise of K-Style’ by Fiona Bae, (Thames & Hudson), will be published in the UK & Ireland on 22 September 2022...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...But many question if the balance of power has tipped too far in Pfizer’s favour....
...Other vaccines may also have greater longevity than Pfizer’s, with two studies suggesting the Oxford/AstraZeneca jab’s efficacy wanes more slowly than Pfizer’s, albeit from a lower initial rate....
...What’s missing is an integrated smartphone mount to aid with viewing the app, but you could add one yourself or wait for the V, which will include one....
...Reach out to me (imani.moise@ft.com) or Sid (sid.v@ft.com) to let us know. Happy reading!...
...That turned out to be a miscalculation, I suggest, given Netanyahu went on to lose power. “Maybe,” says Bourla. “But he did it very well.” Our main courses arrive....
...Write to the FintechFT team at imani.moise@ft.com and sid.v@ft.com....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Belgrade has so far relied heavily on China’s Sinopharm jab and Russia’s Sputnik V but it is also deploying BioNTech/Pfizer and Oxford/AstraZeneca vaccines imported from the EU. “How can they do this?...
...Solid growth in the final quarter of the year left output just 1 per cent below the same period in 2019, highlighting the speed of the bounce back from last year’s downturn, and suggesting a “V-shaped” recovery...
...As a result Serbia is among the first European countries to administer jabs made in China, alongside Russia’s Sputnik V, Pfizer, AstraZeneca and Moderna....
...Kuala Lumpur also has agreements with Russia, for the Sputnik V vaccine, and with AstraZeneca....
International Edition